Tracking Immunity After the Payload: Longitudinal Biomarkers for Rational ADC Immunotherapy Combinations

• Distinguishing clinical activity from true immune synergy, examining how to separate an additive response from a genuine interaction so developers can make combination decisions earlier and with more confidence
• Exploring how payload-driven cell death releases antigen, drives presentation and triggers T-cell expansion, and which of these steps can be reliably measured in patients
• Assessing how biomarker data can guide the choice of partner, and the sequencing that follows

Speakers: